Mostrar el registro sencillo del ítem

dc.contributor.authorÁlvarez Mon, M. A.
dc.contributor.authorGutiérrez Rojas, Luis 
dc.date.accessioned2023-03-27T08:20:30Z
dc.date.available2023-03-27T08:20:30Z
dc.date.issued2023-02-15
dc.identifier.citationAlvarez-Mon, M.A... [et al.]. Current Opinions about the Use of Duloxetine: Results from a Survey Aimed at Psychiatrists. Brain Sci. 2023, 13, 333. [https://doi.org/10.3390/brainsci13020333]es_ES
dc.identifier.urihttps://hdl.handle.net/10481/80861
dc.description.abstractMajor depressive disorder (MDD) is a complex psychiatric disorder that, presented alone or with other comorbidities, requires different adjustments of antidepressant treatments. Some investigations have demonstrated that psychoactive drugs, such as serotonin and norepinephrine reuptake inhibitors (SNRIs), can exert more effective and faster antidepressant effects than other common medications used, such as serotonin selective reuptake inhibitors (SSRIs), although these differences are still controversial. During the last five years, the SNRI duloxetine has shown favorable results in clinical practice for the treatment of MDD, anxiety, and fibromyalgia. Through an online selfcompleted survey, in the present article, we collected information from 163 psychiatrists regarding the use of duloxetine and its comparison with other psychiatric drugs, concerning psychiatrists’ knowledge and experience, as well as patients’ preferences, symptoms, and well-being. We discussed and contrasted physicians’ reports and the scientific literature, finding satisfactory concordances, and finally concluded that there is agreement regarding the use of duloxetine, not only due to its tolerability and effectiveness but also due to the wide variety of situations in which it can be used (e.g., somatic symptoms in fibromyalgia, diabetes) as it relieves neuropathic pain as well.es_ES
dc.description.sponsorshipComunidad de Madrid P2022/BMD-7321es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAtribución 4.0 Internacional*
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectDuloxetinees_ES
dc.subjectMajor depressive disorder (MDD)es_ES
dc.subjectReal world dataes_ES
dc.subjectSerotonin and norepinephrine reuptake inhibitors (SNRIs)es_ES
dc.titleCurrent Opinions about the Use of Duloxetine: Results from a Survey Aimed at Psychiatristses_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.3390/brainsci13020333
dc.type.hasVersionVoRes_ES


Ficheros en el ítem

[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional